Openness and transparency are important considerations for medicines regulators, where public health is of paramount concern. As part of their commitment to transparency, the European Medicines Agency (EMA) and Therapeutic Goods Administration (TGA) in Australia publish information relating to their evaluation of medicines via public assessment reports. European Public Assessment Reports (EPARs) and Australian Public Assessment Reports (AusPARs) provide information about the considerations that led the regulator to approve or refuse the application. The reports summarise assessments by each regulator of the information provided on the quality, safety, and efficacy of the medicine under evaluation. Here, we describe the experiences of two es...
The Internet is becoming the greatest source of health information for most consumers, which reinfor...
Based on an analysis of relevant laws and policies, regulator data portals, and information requests...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
Openness and transparency are important considerations for medicines regulators, where public health...
Over the past 10 years, European pharmaceutical regulators (especially the European Medicines Agency...
Over the past 10years, European pharmaceutical regulators (especially the European Medicines Agency ...
Transparency has risen to prominence in risk regulation leading government authorities in Europe and...
Background Information about the safety of medicines often emerges after approval. Medicines’ regul...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
Over the last couple of decades, the European Union has enacted several pieces of legislation to imp...
AbstractIn response to a recommendation from the Pharmaceutical Forum, the European Medicines Agency...
Objectives: Health regulators have progressively increased their attention and focus on patient-repo...
Following a review process lasting almost four years, and culminating in several pieces of new Europ...
Following a review process lasting almost four years, and culminating in several pieces of new Europ...
The Internet is becoming the greatest source of health information for most consumers, which reinfor...
Based on an analysis of relevant laws and policies, regulator data portals, and information requests...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
Openness and transparency are important considerations for medicines regulators, where public health...
Over the past 10 years, European pharmaceutical regulators (especially the European Medicines Agency...
Over the past 10years, European pharmaceutical regulators (especially the European Medicines Agency ...
Transparency has risen to prominence in risk regulation leading government authorities in Europe and...
Background Information about the safety of medicines often emerges after approval. Medicines’ regul...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
Over the last couple of decades, the European Union has enacted several pieces of legislation to imp...
AbstractIn response to a recommendation from the Pharmaceutical Forum, the European Medicines Agency...
Objectives: Health regulators have progressively increased their attention and focus on patient-repo...
Following a review process lasting almost four years, and culminating in several pieces of new Europ...
Following a review process lasting almost four years, and culminating in several pieces of new Europ...
The Internet is becoming the greatest source of health information for most consumers, which reinfor...
Based on an analysis of relevant laws and policies, regulator data portals, and information requests...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...